BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Modest PFS Improvement For Trastuzumab Pamirtecan; Higher ILD Rate, OS Data Not Mature, Benefit Limited
Share
Why It Matters
BioNTech's new cancer medicine worked better than the old one. But the improvement was small, and it caused more lung problems.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.